Prominent publications by Giorgio Walter Canonica

KOL Index score: 26321

BACKGROUND: To date, no studies have assessed the efficacy of single-inhaler triple therapy in asthma. Here we report on two studies that compared the single-inhaler extrafine combination of beclometasone dipropionate (BDP; inhaled corticosteroid), formoterol fumarate (FF; long-acting β2 agonist), and glycopyrronium (G; long-acting muscarinic antagonist) with the combination of BDP with FF.

METHODS: Two parallel-group, double-blind, randomised, active-controlled, phase 3 trials (Triple ...

Also Ranks for: Uncontrolled Asthma |  trigger bdp |  triple therapy |  single inhaler |  52 weeks
KOL Index score: 25534

BACKGROUND: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life, often requiring recurring systemic corticosteroid use and repeated sinus surgery. Dupilumab is a fully human monoclonal antibody that inhibits signalling of interleukin (IL)-4 and IL-13, key drivers of type 2 inflammation, and has been approved for use in atopic dermatitis and asthma. In these two studies, we aimed to assess efficacy ...

Also Ranks for: Dupilumab Patients |  nasal polyps |  24 weeks |  3 trials |  severe chronic
KOL Index score: 18889

Five biologicals have been approved for severe eosinophilic asthma, a well-recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of care for severe eosinophilic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated for ...

Also Ranks for: Severe Eosinophilic Asthma |  benralizumab dupilumab |  mepolizumab reslizumab |  eaaci guidelines |  moderate certainty
KOL Index score: 17959

BACKGROUND: Allergic Rhinitis and its Impact on Asthma in collaboration with the World Health Organization initiative reclassified allergic rhinitis, like asthma, by duration and severity. The Xyzal in Persistent Rhinitis Trial is the first large, long-term clinical trial studying patients with persistent rhinitis as defined by Allergic Rhinitis and its Impact on Asthma.

OBJECTIVES: Two primary objectives were defined: comparison of the Rhinoconjunctivitis Quality of Life Questionnaire ...

Also Ranks for: Allergic Rhinitis |  quality life |  comorbidities costs |  levocetirizine placebo |  impact asthma
KOL Index score: 16505

BACKGROUND: Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with significant unmet medical need. We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids) in the first omalizumab study to exclusively enrol patients from this difficult-to-treat patient population.

METHODS: Following a run-in phase, patients ...

Also Ranks for: Inadequately Controlled |  severe persistent |  add‐on therapy |  monoclonal antibodies |  omalizumab placebo
KOL Index score: 16231

BACKGROUND: Treatment guidelines recommend the regular use of inhaled corticosteroids for patients with mild persistent asthma. We investigated whether the symptom-driven use of a combination of beclomethasone dipropionate and albuterol (also known as salbutamol) in a single inhaler would be as effective as the regular use of inhaled beclomethasone and superior to the as-needed use of inhaled albuterol.

METHODS: We conducted a 6-month, double-blind, double-dummy, randomized, ...

Also Ranks for: Single Inhaler |  mild asthma |  beclomethasone albuterol |  therapy needed |  inhalation adrenergic
KOL Index score: 15313

BACKGROUND: The clinical safety of sublingual immunotherapy (SLIT) has been repeatedly confirmed; nevertheless, the possible onset of local oral symptoms is still a concern, and nothing is known about the pathogenesis of this effect. We aimed to determine whether the administration of SLIT in allergic children can evoke an IgE-mediated reaction, by measuring the levels of sublingual tryptase and ECP.

METHODS: Thirty children (7-12 years old) with allergic rhinitis/asthma due to grass ...

Also Ranks for: Ecp Slit |  nasal tryptase |  grass pollen |  6 months |  allergic subjects
KOL Index score: 14663

BACKGROUND: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms.

METHODS: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18-75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional ...

Also Ranks for: Lung Function |  benralizumab patients |  eosinophilic asthma |  nasal polyposis |  exacerbation rate
KOL Index score: 14302

BACKGROUND: Investigations meeting current standards are limited for the effect of house dust mite (HDM) allergy immunotherapy in asthmatic patients.

OBJECTIVE: This trial investigated the efficacy and safety of a standardized quality (SQ; allergen standardization method proprietary to the trial sponsor) HDM SLIT-tablet (ALK, Hørsholm, Denmark) in adults and adolescents with HDM respiratory allergic disease. This publication reports the results of the endpoints related to ...

Also Ranks for: Asthma Control |  inhaled corticosteroid |  standardized quality |  inhalation administration |  6 sqhdm
KOL Index score: 13865

This guideline, together with its sister guideline on the management of urticaria [Zuberbier T, Asero R, Bindslev-Jensen C, Canonica GW, Church MK, Giménez-Arnau AM et al. EAACI/GA(2)LEN/EDF/WAO Guideline: Management of urticaria. Allergy, 2009; 64:1427-1443] is the result of a consensus reached during a panel discussion at the 3rd International Consensus Meeting on Urticaria, Urticaria 2008, a joint initiative of the Dermatology Section of the European Academy of Allergology and ...

Also Ranks for: Urticaria Guideline |  definition classification |  child child |  european academy |  clinical immunology
KOL Index score: 13793

BACKGROUND: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19.

METHODS: We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 ...

Also Ranks for: Sarilumab Patients |  primary endpoint |  critical covid19 |  respiratory distress syndrome |  phase 3
KOL Index score: 13690

BACKGROUND: Levocetirizine and desloratadine are newer antihistamines indicated for the treatment of allergic rhinitis and chronic idiopathic urticaria.

OBJECTIVE: This article discusses the pharmacokinetics and pharmacodynamics of levocetirizine and desloratadine and reviews studies that have directly compared the effects of these 2 drugs in allergic rhinitis and urticaria.

METHODS: Relevant articles were identified through a search of MEDLINE from 1999 through 2004 using the main ...

Also Ranks for: Allergic Rhinitis |  levocetirizine desloratadine |  chronic idiopathic urticaria |  faster onset |  histamine antagonists
KOL Index score: 13345

RATIONALE: Several randomized, double-blind, placebo-controlled clinical trials have demonstrated the efficacy of mometasone furoate nasal spray (MFNS) in the treatment of allergic rhinitis (AR) thus allowing for a meta-analysis to determine the overall treatment effect.

METHODS: A comprehensive search of the MEDLINE, LILACS, SCOPUS, and the Cochrane Library databases up to 31 October, 2007 was carried out. Randomized, double-blind, placebo-controlled, clinical trials evaluating the ...

Also Ranks for: Mometasone Furoate |  nasal spray |  mfns treatment |  perennial rhinitis |  allergic seasonal administration
KOL Index score: 13116

BACKGROUND: The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines proposed a classification for allergic rhinitis based on the duration of symptoms (intermittent, persistent) rather than on the time of allergen exposure (seasonal, perennial). There is no placebo-controlled, randomized clinical trial on intermittent allergic rhinitis (IAR) to date. Desloratadine (DL) is recommended for the first-line treatment of seasonal and perennial allergic rhinitis.

OBJECTIVES: To assess ...

Also Ranks for: Allergic Rhinitis |  life placebo |  efficacy desloratadine |  seasonal severity |  therapeutic response

Key People For Allergic Rhinitis

Top KOLs in the world
JeanClaude ********
allergic rhinitis asthma control chronic respiratory diseases
Giorgio ****** ********
allergic rhinitis severe asthma sublingual immunotherapy
Eli * *******
allergic rhinitis fluticasone propionate united states
Paul * *** ***********
allergic rhinitis nasal polyps chronic rhinosinusitis
Claus *******
nasal polyps chronic rhinosinusitis allergic rhinitis
Alkis * ******
allergic rhinitis peanut allergy infectious diseases

Giorgio Walter Canonica:Expert Impact

Concepts for whichGiorgio Walter Canonicahas direct influence:Allergic rhinitis,  Severe asthma,  Sublingual immunotherapy,  Allergen immunotherapy,  Respiratory allergy,  Asthma control,  Perennial rhinitis,  Allergic diseases.

Giorgio Walter Canonica:KOL impact

Concepts related to the work of other authors for whichfor which Giorgio Walter Canonica has influence:Allergic rhinitis,  Severe asthma,  Sublingual immunotherapy,  Chronic urticaria,  Atopic dermatitis,  Food allergy,  Nasal polyps.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Personalized Medicine, Asthma and Allergy, Humanitas University and Research Hospital, Rozzano, Milan, Italy | Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Italy | Departmento of Biomedical Sciences - Humanit